Notice ID: 64475df9ce3c4c9590e2b3a925cb1167Combined Synopsis/Solicitation
SARS-CoV2 3CL protease cell-based assay development for drug screening
Archived on June 26, 2020. Original response deadline: . Full description on SAM.gov.
Overview
- Response deadline
- 11:59 AM UTC−04:00
- Posted
- June 5, 2020
- Notice type
- Combined Synopsis/Solicitation
- Set-aside
- Total Small Business Set-Aside (FAR 19.5)
- NAICS
- 541380: Testing Laboratories and Services
- Agency
- Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH
Notice details
- Office
- NATIONAL INSTITUTES OF HEALTH NIDA
- Last updated
- Sep 9, 2025
Identifiers
- Solicitation number
- 75N95020Q00142
- Notice ID
- 64475df9ce3c4c9590e2b3a925cb1167
Description
The National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) requires SARS-CoV2 3CL protease cell-based assay development for drug screening to support efforts related to COVID-19. This requirement includes assay development, stable cell line generation and selection by luciferase activity as outlined in the Statement of Work. See attached CSS and Statement of Work.
Award Overview
No prior contract identified
No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.
Contacts
Documents
No documents available.
Lifecycle
Solicitation:
75N95020Q00142- Combined Synopsis
- Combined SynopsisCurrentJun 5, 2020
SARS-CoV2 3CL protease cell-based assay development for drug screening
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
Additional Details
Solicitation Number
75N95020Q00142
Archive Date
Jun 26, 2020
Office Address
Bethesda, MD, 20892